First Patient dosed in Ph 1/2a Clinical Trial of BPT567 in patients with solid tumors October 22, 2024
US FDA issues Study May Proceed letter for the Pilot Study of Pidnarulex PD in Patients with Advanced Solid Tumors October 22, 2024
Nona Biosciences announced a strategic collaboration with OverT Bio to develop next-generation cell therapies for solid tumors October 15, 2024
CRLs submitted to request lifting the clinical holds for zevorcabtagene autoleucel, satricabtagene autoleucel and CT071 October 15, 2024
Cellipont Bioservices and Mongoose Bio to Advance TCR-T therapy MGB-001 for Multiple Cancers October 9, 2024
ABL Bio Announces Clinical Collaboration to Evaluate ABL103 in Combination with KEYTRUDA in Patients with Solid Tumors October 8, 2024
Ph 1 Data of Concurrent Paxalisib + RT in Patients with Solid Tumor Brain Mets or Leptomeningeal Mets Harboring PI3K Pathway Mutations announced October 8, 2024
FDA Clears IND Application for REC-1245, a RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma October 8, 2024
Enrollment completed in Ph 2 proof of concept 065-101 study of fadraciclib in patients with advanced solid tumors and lymphoma; ongoing in T-Cell Lymphoma cohort October 2, 2024
Positive Initial Safety, Tolerability, PK, and Preliminary Efficacy Data announced from Ph 1 Trial of PAS-004 in Advanced Cancer October 1, 2024
Nona Biosciences Enters Strategic Collaboration with Alkyon Therapeutics for Next-Gen Immunotherapeutics Discovery September 25, 2024
GlyTherix to Partner with SHINE Technologies for Advancing Targeted Radiotherapy in Aggressive Cancers September 24, 2024
Deltacel-01 Advanced Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation September 24, 2024
Ph 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study Announced September 24, 2024
Neoadjuvant TAR-200 + cetrelimab nearly doubles the pCRR compared to cetrelimab alone in patients with MIBC September 24, 2024
IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI September 24, 2024
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-based Radiopharmaceutical Programs Targeting Solid Tumors September 18, 2024
